Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome

JAMA

Volumn 302, Issue 11, 2009, Pages 1210-1217

  Charakida, Marietta ^a   Besler, Christian ^b   Batuca, Joana R ^c   Sangle, Shirish ^d   Marques, Susanna ^d   Sousa, Miguel ^d   Wang, Guosu ^a   Tousoulis, Dimitris ^e   Delgado Alves, Jose ^c   Loukogeorgakis, Stavros P ^a   Mackworth Young, Charles ^f   D'Cruz, David ^d   Luscher, Thomas ^b   Landmesser, Ulf ^b   Deanfield, John E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY; SUPEROXIDE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; AORTA; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR RISK; CELL ADHESION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOCYTE; PRIORITY JOURNAL; PULSE WAVE; VASCULAR DISEASE; VASODILATATION;

EID: 70349116054     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1346     Document Type: Article

References (39)

1. Hughes G. Hughes syndrome: the antiphospholipid syndrome - a clinical overview. Clin Rev Allergy Immunol. 2007;32(1):3-12. (Pubitemid 46594571)
2. Mackworth-Young C. Primary antiphospholipid syndrome: a distinct entity? Autoimmun Rev. 2006;5(1):70-75. (Pubitemid 41759445)
3. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005;64(2):315-317. (Pubitemid 40193636)
4. Dropiński J, Szczeklik W, Rubis P, Sydor WJ. Antiphospholipid antibodies and carotid-artery intimamedia thickness in young survivors of myocardial infarction. Med Sci Monit. 2003;9(4):BR105-BR109. (Pubitemid 36565363)
5. Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus. 2002;11(4):208-214. (Pubitemid 34506724)
6. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112(21):3337-3347. (Pubitemid 43739380)
7. Delgado Alves J, Ames PR, Donohue S, et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum. 2002;46(10):2686-2694. (Pubitemid 36118933)
8. Delgado Alves J, Mason LJ, Ames PR, et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model. Rheumatology (Oxford). 2005;44(10):1238-1244. (Pubitemid 41487956)
9. Lambert M, Boullier A, Hachulla E, et al. Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus. 2000;9(4):299-300. (Pubitemid 30261072)
10. Batuca JR, Ames PR, Amaral M, Favas C, Isenberg DA, Delgado Alves J. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford). 2009;48(1):26-31.
11. Charakida M, Donald AE, Green H, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation. 2005;112(1):103-109. (Pubitemid 40962575)
12. Donald AE, Charakida M, Cole TJ, et al. Noninvasive assessment of endothelial function: which technique? J Am Coll Cardiol. 2006;48(9):1846-1850. (Pubitemid 44648611)
13. Sorrentino SA, Bahlmann FH, Besler C, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 2007;116(2):163-173. (Pubitemid 47057522)
14. Jara LJ, Medina G, Vera-Lastra O, Amigo MC. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev. 2006;5(3):195-201. (Pubitemid 43234184)
15. Pahor A, Hojs R, Holc I, et al. Antiphospholipid antibodies as a possible risk factor for atherosclerosis in patients with rheumatoid arthritis. Immunobiology. 2006;211(9):689-694. (Pubitemid 44464020)
16. Nicolo D, Monestier M. Antiphospholipid antibodies and atherosclerosis. Clin Immunol. 2004;112(2):183-189.
17. Gordon PA, George J, Khamashta MA, Harats D, Hughes G, Shoenfeld Y. Atherosclerosis and autoimmunity. Lupus. 2001;10(4):249-252.
18. Matsuura E, Kobayashi K, Tabuchi M, Lopez LR. Accelerated atheroma in the antiphospholipid syndrome. Rheum Dis Clin North Am. 2006;32(3):537-551.
19. Vlachoyiannopoulos PG, Samarkos M. Peripheral vascular disease in antiphospholipid syndrome. Thromb Res. 2004;114(5-6):509-519. (Pubitemid 39422585)
20. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol. 2006;2(2):99-106. (Pubitemid 43239209)
21. Levy PJ, Cooper CF, Gonzalez MF. Massive lower extremity arterial thrombosis and acute hepatic insufficiency in a young adult with premature atherosclerosis associated with hyperlipoprotein(a)emia and antiphospholipid syndrome: a case report. Angiology. 1995;46(9):853-858.
22. Sherer Y, Shoenfeld Y. Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis? Immunobiology. 2003;207(1):13-16. (Pubitemid 36285090)
23. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459-467. (Pubitemid 46184197)
24. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patient. Circulation. 2004;110(14):1926-1932.
25. Dropiński J, Szczeklik W, Wegrzyn W. Increased carotid artery intima-media thickness as an indicator of the onset of atherosclerosis in patients with connective tissue systemic diseases. Kardiol Pol. 2003;59(12):475-483.
26. Medina G, Casaos D, Jara LJ, et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis. 2003;62(7):607-610. (Pubitemid 36760555)
27. Ames PR, Delgado Alves J, Lopez LR, et al. Antibodies against beta2-glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome. Clin Dev Immunol. 2006;13(1):1-9.
28. Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus. 1998;7(5):355-360. (Pubitemid 28347016)
29. Delgado Alves J, Kumar S, Isenberg DA. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford). 2003;42(7):893-899. (Pubitemid 37220940)
30. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394(6690):284-287. (Pubitemid 28335041)
31. Tward A, Xia YR, Wang XP, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106(4):484-490. (Pubitemid 34803695)
32. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299(11):1265-1276.
33. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7(7):853-857. (Pubitemid 32691642)
34. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108(22):2751- 2756. (Pubitemid 37498976)
35. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 2001;103(18):2283-2288. (Pubitemid 32433719)
36. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007;18(4):427-434.
37. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23(4):370-378.
38. Aviram M, Rosenblat M. Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol. 2008;477:259-276.
39. Feng H, Li XA. Dysfunctional high-density lipoprotein. Curr Opin Endocrinol Diabetes Obes. 2009;16(2):156-162.